SCHEMBL25323637

SCHEMBL25323637

CC1CCC(c2ccccc2)N(C(=O)C(=O)Nc2cnc(N)c3c2CO[C@@H]3C)C1

nearest known ligand 0.61

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 20/20 0.61
WDR77 Q9BQA1 4/20 0.52
KCNH2 Q12809 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25906741 1.00 PRMT5 (0.61) PRMT5WDR77KCNH2
SCHEMBL25917792 1.00 PRMT5 (0.61) PRMT5WDR77KCNH2
SCHEMBL30551057 1.00 PRMT5 (0.61) PRMT5WDR77KCNH2
SCHEMBL25325603 1.00 PRMT5 (0.61) PRMT5WDR77KCNH2
SCHEMBL25319837 0.87 PRMT5 (0.65) PRMT5WDR77KCNH2
SCHEMBL25319839 0.87 PRMT5 (0.65) PRMT5WDR77KCNH2
SCHEMBL25932520 0.86 PRMT5 (0.42) PRMT5WDR77
SCHEMBL25906828 0.86 PRMT5 (0.42) PRMT5WDR77
SCHEMBL25318915 0.84 PRMT5 (0.67) PRMT5WDR77
SCHEMBL30551157 0.84 PRMT5 (0.67) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN PRMT5 562/4885WDR77 1925/4885KCNH2 2089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.